Literature DB >> 30358625

Predictive Value of FDG PET/CT Versus Bone Marrow Biopsy in Pediatric Lymphoma.

Salma Badr, Magdy Kotb, Mai Amr Elahmadawy, Hosna Moustafa1.   

Abstract

PURPOSE: The aim of this study was to explore the positive predictive value and negative predictive value of FDG PET/CT. The prognostic impact of tumor burden of bone marrow infiltrates was diagnosed by FDG PET/CT at initial presentation.
METHODS: This retrospective study enrolled 140 pediatric patients with pathologically proven lymphoma (113 Hodgkin disease and 27 Non-Hodgkin lymphoma). All patients had pretherapy FDG PET/CT. Bone marrow biopsy (BMB), clinical, radiological, and follow-up data were also collected. The skeleton was divided into 8 segments, and a 5-point scoring system was used for assessment of BM infiltration burden.
RESULTS: Among the 140 lymphoma patients, FDG PET/CT revealed positive BM involvement in 41 patients; 2 of them were false-positive with negative BMB and regional MRI results. Positive predictive value was 95.1% for PET/CT compared with 100% with BMB. All patients diagnosed with positive BMI by BMB were detected by FDG PET/CT. On the contrary, BMB missed 25 patients (17.9%) with statistically significant difference. Negative predictive value was 100% for PET/CT compared with 80.2% for BMB (P < 0.05). FDG PET/CT upstaged 17.9% of the enrolled patients. Bone marrow involvement based on the 5-point scoring system was assessed. No significant difference was demonstrated in therapy outcome between patient with focal BMI (score 2) and extensive BMI (score 5; P = 0.06).
CONCLUSIONS: FDG PET/CT has optimum negative predictive value compared with BMB in detection of bone marrow infiltrations in pediatric lymphoma with upstaging cases missed with BMB. Prognostic impact of BMI based on the 5-point scoring system reveals that the main influence is presence or absence of BMI rather than its tumor burden.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30358625     DOI: 10.1097/RLU.0000000000002315

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  6 in total

1.  PET/MRI Improves Management of Children with Cancer.

Authors:  Lucia Baratto; K Elizabeth Hawk; Lisa States; Jing Qi; Sergios Gatidis; Louise Kiru; Heike E Daldrup-Link
Journal:  J Nucl Med       Date:  2021-10       Impact factor: 10.057

2.  Diagnostic Accuracy of 2-[18F]FDG-PET and whole-body DW-MRI for the detection of bone marrow metastases in children and young adults.

Authors:  Ali Rashidi; Lucia Baratto; Ashok Joseph Theruvath; Elton Benjamin Greene; K Elizabeth Hawk; Rong Lu; Michael P Link; Sheri L Spunt; Heike E Daldrup-Link
Journal:  Eur Radiol       Date:  2022-01-31       Impact factor: 7.034

3.  Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation.

Authors:  Yong-Jin Park; Seung Hyup Hyun; Seung Hwan Moon; Kyung-Han Lee; Byung Hoon Min; Jun Haeng Lee; Won Seog Kim; Seok Jin Kim; Joon Young Choi
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

4.  The Diagnostic Value of 18F-FDG PET/CT Bone Marrow Uptake Pattern in Detecting Bone Marrow Involvement in Pediatric Neuroblastoma Patients.

Authors:  Jun Liu; Cuicui Li; Xu Yang; Xia Lu; Mingyu Zhang; Luodan Qian; Wei Wang; Ying Kan; Jigang Yang
Journal:  Contrast Media Mol Imaging       Date:  2022-01-06       Impact factor: 3.161

5.  18F-FDG PET/CT-based radiomics nomogram could predict bone marrow involvement in pediatric neuroblastoma.

Authors:  Lijuan Feng; Xu Yang; Xia Lu; Ying Kan; Chao Wang; Dehui Sun; Hui Zhang; Wei Wang; Jigang Yang
Journal:  Insights Imaging       Date:  2022-09-04

Review 6.  FDG-PET/CT versus bone marrow biopsy in bone marrow involvement in newly diagnosed paediatric lymphoma: a systematic review and meta-analysis.

Authors:  Zhizhuo Li; Chengxin Li; Bingrong Chen; Lijun Shi; Fuqiang Gao; Peixu Wang; Wei Sun
Journal:  J Orthop Surg Res       Date:  2021-08-09       Impact factor: 2.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.